In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TherOx: Building a Device Platform on Thin Air

Executive Summary

TherOx was founded upon a simple, compelling notion-that large quantities of oxygen can be saturated into fluids to form aqueous oxygen. But while the benefits of salvaging ischemic tissue by providing oxygen are well known, solving the delivery problem took longer than even TherOx expected, as did subsequent engineering and regulatory approval issues. In the meantime, the company's initial target market became less attractive because of subsequent device developments, notably coronary stents. TherOx is now focused on a new, huge clinical opportunity-acute myocardial infarctions. What has sustained the company through eight years of progress and disappointment is the promise of a true platform technology with applications in a variety of large, diverse markets. The company therefore provides an answer to the question: How does a device start-up take eight years just to get to Phase II clinical trials and still survive?

You may also be interested in...



Changing Minds at the FDA

Visioncare's recent success in getting an FDA advisory panel to change a recommendation is a rare and noteworthy achievement. But the agency could prove to be an even more formidable barrier - and a potential catalyst for change - for the device sector going forward.

Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge

Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel